Abstract Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation
vaccine against smallpox and serves as a potent vector system for development of new …

Humans have a close phylogenetic relationship with nonhuman primates (NHPs) and share
many physiological parallels, such as highly similar immune systems, with them. Importantly …

HIV-1 infection typically results from the transmission of a single viral variant, the
transmitted/founder (T/F) virus. Studies of these HIV-1 variants provide critical information …

Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …

Preclinical studies of viral vector–based HIV-1 vaccine candidates have previously shown
partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this …

A successful HIV-1 vaccine will require induction of a polyclonal neutralizing antibody (nAb)
response, yet vaccine-mediated induction of such a response in primates remains a …

Antibodies are the primary correlate of protection for most licensed vaccines; however, their
mechanisms of protection may vary, ranging from physical blockade to clearance via the …

Organisms are adapted to the relentless cycles of day and night, because they evolved
timekeeping systems called circadian clocks, which regulate biological activities with~ 24 …

Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …

RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …